Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Capital Expenditures (2020 - 2024)

Gain Therapeutics has reported Capital Expenditures over the past 5 years, most recently at $945.0 for Q4 2024.

  • Quarterly results put Capital Expenditures at $945.0 for Q4 2024, up 4873.68% from a year ago — trailing twelve months through Dec 2024 was $1615.0 (down 89.48% YoY), and the annual figure for FY2024 was $22493.0, up 46.46%.
  • Capital Expenditures for Q4 2024 was $945.0 at Gain Therapeutics, up from $1.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for GANX hit a ceiling of $57179.0 in Q3 2022 and a floor of -$38.0 in Q2 2020.
  • Median Capital Expenditures over the past 5 years was $8611.5 (2022), compared with a mean of $13905.3.
  • Biggest five-year swings in Capital Expenditures: soared 59318.42% in 2021 and later plummeted 99.85% in 2024.
  • Gain Therapeutics' Capital Expenditures stood at $14551.0 in 2020, then fell by 23.73% to $11098.0 in 2021, then decreased by 15.32% to $9398.0 in 2022, then plummeted by 99.8% to $19.0 in 2023, then soared by 4873.68% to $945.0 in 2024.
  • The last three reported values for Capital Expenditures were $945.0 (Q4 2024), $1.0 (Q3 2024), and $19.0 (Q4 2023) per Business Quant data.